Abstract
Discovering novel biomarkers that easily accessed is a key step towards the personalized medicine approach for gastric cancer patients. Integrin-β6 (ITGB6) is a subtype of integrin that is exclusively expressed on the surface of epithelial cells and is up-regulated in various tumors. In the present study, a retrospective cohort with 135 gastric cancer patients and a prospective cohort with 34 gastric cancer patients were constructed, ITGB6 expression were detected in both the serum specimens and the tissue specimens. Detailed clinicopathological parameters as well as patients’ survival were recorded. A nomogram including ITGB6 expression was also constructed and validated to predict the prognosis of gastric cancer patients. Results showed that serum ITGB6 expression was obviously increased and associated with tumor stage in gastric cancer patients, serum ITGB6 expression was relatively high in patients with liver metastasis. High ITGB6 expression indicated a poor prognosis, and nomogram including serum ITGB6 expression could predict the prognosis of gastric cancer patients effectively. Moreover, serum ITGB6 expression was associated with ITGB6 expression in tumor tissues. Furthermore, combined serum ITGB6 and CEA levels contributed to the risk stratification and prognostic prediction for gastric cancer patients. In addition, the serum expression of ITGB6 decreased significantly after radical surgery, and a new rise in serum ITGB6 expression indicated tumor recurrence or progression. The present study identified a novel serum biomarker for the risk stratification, prognostic prediction and surveillance of gastric cancer patients.
Highlights
Gastric cancer is the fifth most commonly diagnosed cancer and the third leading cause of cancerrelated death worldwide [1, 2]
To explore whether ITGB6 could be detected in the serum of gastric cancer patients, we investigated serum ITGB6 levels in a retrospective cohort containing 135 gastric cancer patients
Results showed that ITGB6 could be detected in the serum of gastric cancer patients, which ranged from 0-5.16ng/ml, and serum ITGB6 levels were significantly increased in gastric cancer patients (Figure 1A)
Summary
Gastric cancer is the fifth most commonly diagnosed cancer and the third leading cause of cancerrelated death worldwide [1, 2]. ITGB6 expression in gastric cancer tissues was closely associated with tumor stage, it served as an independent prognostic indicator for the poor prognosis of gastric cancer. The present study investigated whether serum ITGB6 level serves as a novel tumor biomarker for gastric cancer patients. Prognostic prediction and recurrence surveillance, we explored the clinical significance of serum ITGB6 levels for gastric cancer patients by both retrospective and prospective cohorts. The ITGB6 mRNA expression data and corresponding clinical information for gastric cancer patients were obtained from The Cancer Genome Atlas (TCGA; https://tcga-data.nci.nih.gov/ tcga/). The differential mRNA expression level of ITGB6 between a variety of cancer tissues and normal ones were obtained using the TIMER database Written informed consent was obtained from each patient, and this study was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University, China. The sections were counterstained with hematoxylin, and representative images were obtained under an Olympus inverted microscope
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
